The antipsoriatic agent dimethylfumarate immunomodulates T-cell cytokine secretion and inhibits cytokines of the psoriatic cytokine network

British Journal of Dermatology

Volumn 139, Issue 3, 1998, Pages 390-395

  Ockenfels, H M ^a,b   Schultewolter, T ^a   Ockenfels, G ^a   Funk, R ^a   Goos, M ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b Klinikum Hanau   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPSORIASIS AGENT; CYTOKINE; EPIDERMAL GROWTH FACTOR; FUMARIC ACID DERIVATIVE; FUMARIC ACID DIMETHYL ESTER; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; PHYTOHEMAGGLUTININ; TRANSFORMING GROWTH FACTOR ALPHA;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOMODULATION; KERATINOCYTE; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS; SKIN BIOPSY; T LYMPHOCYTE ACTIVATION;

ADULT; AGED; BLOTTING, NORTHERN; CELL COMMUNICATION; CELL CULTURE TECHNIQUES; CYTOKINES; FEMALE; FUMARATES; GENE EXPRESSION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PSORIASIS; RNA, MESSENGER; T-LYMPHOCYTES;

EID: 0031661686     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.1998.02400.x     Document Type: Article

References (22)

1. Baker BS, Fry L. The immunology of psoriasis. Br J Dermatol 1993; 126: 1-9.
2. Christophers E. The immunopathology of psoriasis. Int Arch Allergy Immunol 1996; 110: 199-206.
3. Uyemura K, Yamamura M, Fivenson DF et al. The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response. J Invest Dermatol 1993; 101: 701-5.
4. Elder JT, Fisher GJ, Linquist P et al. Overexpression of transforming growth factor-α in psoriatic skin. Science 1998; 243: 811-14.
5. Schweckendiek W. Heilung von Psoriasis vulgaris. Med Monatsschr 1959; 13: 103-4.
6. Altmeyer PJ, Matthes U, Pawlak F et al. Anti-psoriatic effect of fumaric acid derivatives: results of a multicentre double blind study in 100 patients. J Am Acad Dermatol 1994; 30: 977-84.
7. Ockenfels HM, Keim-Maas C, Funk R et al. Ethanol enhances the INF-γ, TGF-α and IL-6 secretion in psoriatic co-cultures. Br J Dermatol 1996; 135: 746-51.
8. Ockenfels HM, Wagner SN, Keim-Maas C et al. Lithium and psoriasis: cytokine modulation of cultured lymphocytes and psoriatic keratinocytes by lithium. Arch Dermatol Res 1996; 288: 173-8.
9. Stoof TJ, Mitra RS, Sharma V et al. Keratinocyte activation following T lymphocyte binding. J Invest Dermatol 1992; 98: 92-5.
10. Fivenson DP, Nickoloff BJ, Sae GM. Quantitative PCR analysis of Th1 cytokines in Hut cells after exposure to PUVA in vitro. J Invest Dermatol 1994; 102: 587. (Abstr.)
11. Ralph P, Nakoinz I, Sampson-Johannes A et al. IL-10. T lymphocyte inhibitor of human blood cell production of IL-1 and TNF-alpha. J Immunol 1992; 148: 808-14.
12. Nibbering PH, Thio B, Zomerdijk TPL et al. Effects of monoethylfumarate on human granulocytes. J Invest Dermatol 1993; 101: 37-42.
13. Sebök B, Bonnekoh B, Geisel J, Mahrle G. Antiproliferative and cytotoxic profiles of antipsoriatic fumaric acid derivates in keratinocyte cultures. Eur J Pharmacol 1994; 270: 79-87.
14. Van der Schroeff JG, Oudshoorn C, Nugteren-Huying WM, Ponec M. Inhibitory effects of fumaric acid derivatives on cell proliferation and differentiation. J Invest Dermatol 1989; 92: 537. (Abstr.)
15. Sarheim BS. Psoriatic libroblasts in cell culture - contribution to the mode of action of fumarates in psoriasis treatment. 1990 Thesis, Swiss Federal Institute of Technology (ETH), Zürich.
16. de Jong R, Bezemer AC, Zomerdijk TPL et al. Selective stimulation of T helper 2 cytokine responses by the anti-psoriasis agent monoethylfumarate. Eur J Immunol 1996; 26: 2067-74.
17. Nieboer CD, de Hoop AC, van Loenen PNJ et al. Systemic treatment with fumaric acid derivatives: new possibilities in the treatment of psoriasis. J Am Acad Dermatol 1989; 20: 601-9.
18. Thio HB, van der Schroeff JG, Nugteren-Huying WM, Vermeer BJ. Long-term systemic therapy with dimethylfumarate and monoethylfumarate (Fumaderm®) in psoriasis. J Eur Acad Dermatol Venereol 1995; 4: 35-40.
19. Grossman RM, Krueger J, Yourish D et al. Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes. Proc Natl Acad Sci U S A 1989; 86: 6367-71.
20. Schmid H, Asadullah A, Döcke WD et al. Monomethylhydrogen-fumarate induces IL-10 secretion of PBMCs from psoriatic patients. Immunobiology 1996; 196: 20. (Abstr.)
21. Bacharach-Buhles M, Pawlak FM, Matthes U et al. Fumaric acid esters (FAEs) suppress CD15- and CD4-positive cells in psoriasis. Acta Derm Venereol (Stockh) 1994; 186: 79-82S.
22. Howard M, O'Garra A. Biological properties of interleukin 10. Immunol Today 1992; 13: 198-200.